Krystal-2: A Phase I/Ii Trial Of Adagrasib (Mrtx849) In Combination With Tno155 In Patients With Advanced Solid Tumors With Kras G12c Mutation.

Joshua K. Sabari,Haeseong Park, Anthony W. Tolcher,Sai-Hong Ignatius Ou,Edward B. Garon,Ben George,Pasi A. Janne,Susan Elizabeth Moody,Eugene Y. Tan,Suman Kumar Sen, Dana Peters,Xiaohong Yan,James G Christensen,Andrew S. Chi,Rebecca Suk Heist

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 29|浏览16

暂无评分

摘要

TPS146Background: KRAS is the most frequently mutated oncogene in cancer and a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRAS G12C tumor mutati...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要